Skip to content
Accessibility help

Search NICE…

Skip to content

Guidance
Standards and indicators
Clinical Knowledge Summaries (CKS)
British National Formulary (BNF)
BNF for Children (BNFC)
Life sciences
More from NICE

Search results

Skip to results

Area of interest

Area of interestAntimicrobial prescribing (40)COVID-19 (35)

Type

TypeGuidance (4954)Indicators (319)News (351)NICE advice (498)Quality standards (257)Research recommendations (1786)

Status

StatusAwaiting development (340)Discontinued (466)In consultation (11)In development (425)Published (2572)Topic prioritisation (384)

Last updated

Last updatedLast 3 months (201)Last 6 months (375)Last year (700)Last 3 years (1434)

Guidance programme

Guidance programmeAntimicrobial prescribing guidelines (27)Antimicrobial resistance guidance (2)Cancer service guidelines (10)Clinical guidelines (392)COVID-19 rapid guidelines (27)Diagnostics guidance (89)Health technology evaluations (60)HealthTech guidance (778)Highly specialised technologies guidance (48)Interventional procedures guidance (1000)Medical technologies guidance (147)Medicines practice guidelines (5)NICE guidelines (579)Public health guidelines (89)Safe staffing guidelines (7)Social care guidelines (47)Technology appraisal guidance (2308)

Advice programme

Advice programmeCOVID-19 rapid summaries (8)Evidence summaries (172)Medtech innovation briefings (324)NICE reviews (2)

Showing 2071 to 2085 of 8908 results

Sort by

Semaglutide for treating obesity-related heart failure with preserved ejection fraction [TSID11788]
Topic prioritisation
Result type
Technology appraisal guidance
Status
Topic prioritisation
Subcutaneous efgartigmod for treating generalised myasthenia gravis [TSID11835]
Topic prioritisation
Result type
Technology appraisal guidance
Status
Topic prioritisation
NPJ5008 for treating malignant hyperthermia [TSID11829]
Topic prioritisation
Result type
Technology appraisal guidance
Status
Topic prioritisation
Baricitinib for treating moderate to severe atopic dermatitis in children and young people aged 2 to 17 [TSID10639]
Topic prioritisation
Result type
Technology appraisal guidance
Status
Topic prioritisation
Subcutaneous belimumab for treating systemic lupus erythematosus in children aged 5 to 17 [TSID11828]
Topic prioritisation
Result type
Technology appraisal guidance
Status
Topic prioritisation
Bardoxolone methyl for treating chronic kidney disease in people 12 years and over with Alport syndrome [TSID9998]
Topic prioritisation
Result type
Technology appraisal guidance
Status
Topic prioritisation
High-dose aflibercept for treating wet age-related macular degeneration [TSID10590]
Topic prioritisation
Result type
Technology appraisal guidance
Status
Topic prioritisation
Semaglutide for treating type 2 diabetes and associated peripheral arterial disease [TSID11791]
Topic prioritisation
Result type
Technology appraisal guidance
Status
Topic prioritisation
Glucarpidase for reducing toxic plasma methotrexate levels in people aged 28 days and over [TSID10761]
Topic prioritisation
Result type
Technology appraisal guidance
Status
Topic prioritisation
Sacubitril valsartan for treating chronic heart failure with reduced ejection fraction in people under 18 years [TSID10350]
Topic prioritisation
Result type
Technology appraisal guidance
Status
Topic prioritisation
Macitentan for treating pulmonary arterial hypertension in people 1 month to 17 years [TSID11805]
Topic prioritisation
Result type
Technology appraisal guidance
Status
Topic prioritisation
TVB-009 (denosumab biosimilar) for treating postmenopausal osteoporosis in people aged 60 to 90 [TSID11807]
Topic prioritisation
Result type
Technology appraisal guidance
Status
Topic prioritisation
Paclitaxel + XR17 (Paclical) with carboplatin for ovarian cancer [TSID5462]
Topic prioritisation
Result type
Technology appraisal guidance
Status
Topic prioritisation
Dupilumab for maintenance treatment of uncontrolled moderate to severe asthma in children 6 to 11 years [TSID10085]
Topic prioritisation
Result type
Technology appraisal guidance
Status
Topic prioritisation
Crizotinib for treating ALK-positive anaplastic large cell lymphoma or inflammatory myofibroblastic tumour in people 6 to 17 years [TSID10574]
Topic prioritisation
Result type
Technology appraisal guidance
Status
Topic prioritisation

Previous page
1
…
137
138
Current page 139
140
141
…
594
Page 139 of 594
Next page

Guidance
Standards and indicators
Clinical Knowledge Summaries (CKS) Clinical Knowledge Summaries
British National Formulary (BNF) British National Formulary
BNF for Children (BNFC) British National Formulary for Children
Life sciences
Library and knowledge services

What NICE does
Implementing NICE guidance
Get involved
About us
Careers
News, blogs and podcasts
Newsletters and alerts
Contact us
Leave feedback
Reusing our content
NICE UK Open Content Licence
Syndicate our content
Events

Facebook
X
YouTube
LinkedIn

Accessibility
Freedom of information
Glossary
Terms and conditions
Privacy notice
Cookies

© NICE 2026. All rights reserved. Subject to Notice of rights.